A new trading day began on Friday, with Akero Therapeutics Inc (NASDAQ: AKRO) stock price up 3.31% from the previous day of trading, before settling in for the closing price of $28.40. AKRO’s price has ranged from $15.32 to $37.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -34.94%. With a float of $58.30 million, this company’s outstanding shares have now reached $69.61 million.
In an organization with 56 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.59%, operating margin of -94813.73%, and the pretax margin is -83528.87%.
Akero Therapeutics Inc (AKRO) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 16.16%, while institutional ownership is 92.02%. The most recent insider transaction that took place on Dec 16 ’24, was worth 29,130. In this transaction Senior VP, Commercial Strategy of this company sold 1,000 shares at a rate of $29.13, taking the stock ownership to the 34,258 shares. Before that another transaction happened on Dec 16 ’24, when Company’s Chief Development Officer sold 9,074 for $29.11, making the entire transaction worth $264,117. This insider now owns 95,648 shares in total.
Akero Therapeutics Inc (AKRO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -34.94% per share during the next fiscal year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Here are Akero Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.16 in the next quarter and is forecasted to reach -4.74 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.9 million. That was better than the volume of 0.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 31.32%. Additionally, its Average True Range was 1.64.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 49.87%, which indicates a significant increase from 42.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.38% in the past 14 days, which was higher than the 49.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.84, while its 200-day Moving Average is $25.92. However, in the short run, Akero Therapeutics Inc’s stock first resistance to watch stands at $30.04. Second resistance stands at $30.75. The third major resistance level sits at $31.72. If the price goes on to break the first support level at $28.36, it is likely to go to the next support level at $27.39. The third support level lies at $26.68 if the price breaches the second support level.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
With a market capitalization of 2.12 billion, the company has a total of 69,799K Shares Outstanding. Currently, annual sales are 0 K while annual income is -151,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -72,710 K.
